Supplement encyclopedia

Ubidecarenone

Coenzyme Q10 is a substance found in the body's cells that participates in energy production. Supplements contain its forms ubiquinone and ubiquinol.

Double-check the conclusions and read the sources before choosing a supplement.

Main conclusion

What it may offer

  • Ubiquinol at a dose of 300 mg after the first of two exercise sessions may reduce muscle soreness the next day and on the third day in untrained men aged 18–30.
  • In healthy adults aged 40 and over, neither ubiquinone nor ubiquinol showed a convincing advantage in ratings of vigour, energy or general health over eight weeks.
  • In physically active men, ubiquinol did not convincingly improve cycling exercise time or measured oxygen-consumption indicators over six weeks.
  • In a small study of women aged 45–60, water-soluble CoQ10 Q10Vital reduced the measured area of wrinkles around the eyes over 12 weeks. No convincing advantage in skin hydration or thickness was found.
  • In adults aged 60 and over, ubiquinol showed no convincing advantage in memory or information-processing-speed tests over 90 days.

[1] [2] [3] [4] [5]

What was studied

  • A review of three studies in healthy adults found no convincing reduction in fatigue with CoQ10. In another trial in working adults, ubiquinol did not convincingly improve the overall self-rated sleep score.
  • A review of studies in athletes found no convincing average advantage in maximum oxygen consumption.
  • A review of studies in middle-aged and older adults, including patients, found no convincing advantage in handgrip strength or the fat-free portion of body weight.
  • A review of studies in adults with different health conditions found no convincing change in body mass index with CoQ10.
  • The Q10Vital trial found no advantage in the ultraviolet dose that causes skin redness.

[1] [2] [3] [4] [5] [6]

Which forms were considered

  • Supplements contain ubiquinone and ubiquinol, different forms of CoQ10. In the study of healthy adults, each form was studied separately at 200 mg a day with food for eight weeks.
  • For skin, water-soluble Q10Vital was used at 50 or 150 mg a day for 12 weeks; the muscle-soreness study used 300 mg of ubiquinol after the first exercise session.

[1] [2] [3]

How to get it from food

  • 100 g of raw pork heart contains about 11.8 mg of CoQ10, and 100 g of raw pork liver about 5.4 mg. These values refer to the foods before cooking.
  • Half a cup of boiled, chopped broccoli contains about 0.5 mg of CoQ10; a tablespoon of soybean oil about 1.3 mg, and of canola oil about 1.0 mg.
  • No official daily intake requirement for CoQ10 has been established. Amounts in food differ from the doses of supplements studied.

[1] [2]

Effects and studied questions

How to read the certainty scale 1–4

Certainty is rated separately for each outcome. 1 is very low, 2 is low, 3 is moderate and 4 is high.

Goal or questionResultConfidenceStudiesPopulation studiedKey sources
Feeling of vigourIn healthy adults aged 40 and over, neither ubiquinone nor ubiquinol showed a convincing advantage in the vigour rating over eight weeks.No significant advantage was reported. The main text gives p>0.44 for secondary outcomes, and the abstract p>0.16.
2/4 LowPrecision of the estimate: The exact CI for each form versus placebo was not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The study tested the specific form, participant group and outcome stated. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Multiple secondary measures in five groups.
11 trial; outcome in the same participant groupA Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Effects of Commercially Available Ubiquinone, Ubiquinol, and Geranylgeraniol Dietary Supplements on Plasma CoQ10 Concentrations ↗150 healthy adults aged 40 and over allocated to five groups
  1. A Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Effects of Commercially Available Ubiquinone, Ubiquinol, and Geranylgeraniol Dietary Supplements on Plasma CoQ10 Concentrations ↗
Vitality questionnaire scoreNeither ubiquinone nor ubiquinol showed a convincing advantage in the vitality rating compared with placebo.No significant advantage was reported. The main text gives p>0.44 for secondary outcomes, and the abstract p>0.16.
2/4 LowPrecision of the estimate: The exact CI for each form versus placebo was not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The study tested the specific form, participant group and outcome stated. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Multiple secondary measures in five groups.
11 trial; outcome in the same participant groupA Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Effects of Commercially Available Ubiquinone, Ubiquinol, and Geranylgeraniol Dietary Supplements on Plasma CoQ10 Concentrations ↗150 healthy adults aged 40 and over allocated to five groups
  1. A Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Effects of Commercially Available Ubiquinone, Ubiquinol, and Geranylgeraniol Dietary Supplements on Plasma CoQ10 Concentrations ↗
General health questionnaire scoreNeither ubiquinone nor ubiquinol showed a convincing advantage in the general health rating compared with placebo.No significant advantage was reported. The main text gives p>0.44 for secondary outcomes, and the abstract p>0.16.
2/4 LowPrecision of the estimate: The exact CI for each form versus placebo was not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The study tested the specific form, participant group and outcome stated. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Multiple secondary measures in five groups.
11 trial; outcome in the same participant groupA Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Effects of Commercially Available Ubiquinone, Ubiquinol, and Geranylgeraniol Dietary Supplements on Plasma CoQ10 Concentrations ↗150 healthy adults aged 40 and over allocated to five groups
  1. A Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Effects of Commercially Available Ubiquinone, Ubiquinol, and Geranylgeraniol Dietary Supplements on Plasma CoQ10 Concentrations ↗

The study count refers to the cited source. Reviews with overlapping trials and outcomes from one study are not added together.

Daily intake requirements and upper limits

Intake and studied regimens
ContextInformation
Intake referencesThere is no established daily intake requirement for CoQ10; the doses studied concern supplements.

Coenzyme Q10 | Linus Pauling Institute | Oregon State University ↗

Forms

Ubiquinone and ubiquinol are different forms of CoQ10; their interconversion does not mean that products are interchangeable. A small study compared blood CoQ10 concentrations after different ubiquinone formulations; this does not prove a clinical advantage for any form.

Guidance for each goal

Feeling of vigour2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: The exact CI for each form versus placebo was not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The study tested the specific form, participant group and outcome stated. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Multiple secondary measures in five groups.

In healthy adults aged 40 and over, neither ubiquinone nor ubiquinol showed a convincing advantage in the vigour rating over eight weeks.

Study findings. In healthy adults aged 40 and over, neither ubiquinone nor ubiquinol showed a convincing advantage in the vigour rating over eight weeks.

Studied regimen200 mg/day of ubiquinone or 200 mg/day of ubiquinol, separate groups, with food200 mg/day of ubiquinone or 200 mg/day of ubiquinol, separate groups, with food
Duration and population8 weeks150 healthy adults aged 40 and over allocated to five groups

Comparison with Placebo

Vitality questionnaire score2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: The exact CI for each form versus placebo was not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The study tested the specific form, participant group and outcome stated. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Multiple secondary measures in five groups.

Neither ubiquinone nor ubiquinol showed a convincing advantage in the vitality rating compared with placebo.

Study findings. Neither ubiquinone nor ubiquinol showed a convincing advantage in the vitality rating compared with placebo.

Studied regimen200 mg/day of ubiquinone or 200 mg/day of ubiquinol, separate groups, with food200 mg/day of ubiquinone or 200 mg/day of ubiquinol, separate groups, with food
Duration and population8 weeks150 healthy adults aged 40 and over allocated to five groups

Comparison with Placebo

General health questionnaire score2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: The exact CI for each form versus placebo was not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The study tested the specific form, participant group and outcome stated. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Multiple secondary measures in five groups.

Neither ubiquinone nor ubiquinol showed a convincing advantage in the general health rating compared with placebo.

Study findings. Neither ubiquinone nor ubiquinol showed a convincing advantage in the general health rating compared with placebo.

Studied regimen200 mg/day of ubiquinone or 200 mg/day of ubiquinol, separate groups, with food200 mg/day of ubiquinone or 200 mg/day of ubiquinol, separate groups, with food
Duration and population8 weeks150 healthy adults aged 40 and over allocated to five groups

Comparison with Placebo

Fatigue in healthy adults1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: small samples, intervals and uncertain clinical relevance Consistency of results: high heterogeneity Applicability to the stated group: the specified form, outcome, clinical background and population limit extrapolation Possible publication bias: asymmetry or incomplete publication Study methods: limitations in the assessment of design, reporting or attrition

Pooling three studies in healthy adults showed no convincing reduction in subjective fatigue.

Study findings. Pooling three studies in healthy adults showed no convincing reduction in subjective fatigue.

Studied regimenMorikawa: 100 mg/day; Mizuno: 100 or 150 mg/day; Mousavi: 200 mg/day.Ubiquinol in the Morikawa and Mizuno studies; CoQ10 in the Mousavi study.
Duration and populationMorikawa: 8 weeks; Mizuno: 12 weeks; Mousavi: 4 weeks.healthy adults, three studies in the subgroup

Comparison: Placebo in each of the three studies in healthy participants.

Time to exhaustion on a cycle ergometer2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: Exact between-group CIs were not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The study tested the specific form, participant group and outcome stated. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Some data are missing; the manufacturer participated in the study.

In physically active men, ubiquinol gave no convincing advantage in cycling exercise time over six weeks.

Study findings. In physically active men, ubiquinol gave no convincing advantage in cycling exercise time over six weeks.

Studied regimenUbiquinol 300 mg/dayUbiquinol 300 mg/day
Duration and population6 weeks54 healthy physically active men randomised

Comparison with Placebo

Oxygen consumption at the end of the cycling test2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: Exact between-group CIs were not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The study tested the specific form, participant group and outcome stated. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Some data are missing; the manufacturer participated in the study.

No convincing difference in oxygen consumption at the end of the cycling test was found in physically active men.

Study findings. No convincing difference in oxygen consumption at the end of the cycling test was found in physically active men.

Studied regimenUbiquinol 300 mg/dayUbiquinol 300 mg/day
Duration and population6 weeks54 healthy physically active men randomised

Comparison with Placebo

Change in oxygen consumption during the cycling test2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: Exact between-group CIs were not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The study tested the specific form, participant group and outcome stated. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Some data are missing; the manufacturer participated in the study.

No convincing difference in the change in oxygen consumption during the cycling test was found.

Study findings. No convincing difference in the change in oxygen consumption during the cycling test was found.

Studied regimenUbiquinol 300 mg/dayUbiquinol 300 mg/day
Duration and population6 weeks54 healthy physically active men randomised

Comparison with Placebo

Maximum oxygen consumption in athletes1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: small samples, intervals and uncertain clinical relevance Consistency of results: insufficient data for a separate downgrade. Applicability to the stated group: the specified form, outcome, clinical background and population limit extrapolation Possible publication bias: insufficient data for a separate downgrade. Study methods: limitations in the assessment of design, reporting or attrition

A review of studies in trained adults found no convincing advantage in maximum oxygen consumption.

Study findings. A review of studies in trained adults found no convincing advantage in maximum oxygen consumption.

Studied regimendifferent doses across studiesoral CoQ10; formulations varied
Duration and populationdurations varytrained healthy adults, 7 studies, 8 comparisons

Comparison with control or placebo in RCTs

Handgrip strength1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: small samples, intervals and uncertain clinical relevance Consistency of results: high heterogeneity Applicability to the stated group: the specified form, outcome, clinical background and population limit extrapolation Possible publication bias: insufficient data for a separate downgrade. Study methods: limitations in the assessment of design, reporting or attrition

Studies in middle-aged and older people found no convincing advantage in handgrip strength.

Study findings. Studies in middle-aged and older people found no convincing advantage in handgrip strength.

Studied regimendoses varyoral CoQ10; forms vary
Duration and populationdurations vary155 adults in four trials with a mean or median age of 40 or over, including patients.

Comparison with control in each RCT

Muscle soreness the next day1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: No numerical magnitude or CI for the between-group effect. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: A narrow protocol of two exercise sessions in untrained men. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Several subgroups, conditions and time points.

In untrained young men after two exercise sessions, next-day soreness was lower with ubiquinol than with placebo.

Study findings. In untrained young men after two exercise sessions, next-day soreness was lower with ubiquinol than with placebo.

Studied regimenUbiquinol 300 mg orally within 10 min after the first exercise, second exercise an hour laterUbiquinol 300 mg orally within 10 min after the first exercise, second exercise an hour later
Duration and populationAssessment on day 1 after the second exercise42 untrained men aged 18–30, 21 each in the normal and elevated BMI groups

Comparison with Placebo in randomised crossover order; separate sports-drink condition

Muscle soreness on the third day1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: No numerical magnitude or CI for the between-group effect. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: A narrow protocol of two exercise sessions in untrained men. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Several subgroups, conditions and time points.

In the same study, soreness on the third day was lower with ubiquinol than with placebo.

Study findings. In the same study, soreness on the third day was lower with ubiquinol than with placebo.

Studied regimenUbiquinol 300 mg orally within 10 min after the first exercise, second exercise an hour laterUbiquinol 300 mg orally within 10 min after the first exercise, second exercise an hour later
Duration and populationAssessment on day 3 after the second exercise42 untrained men aged 18–30, 21 each in the normal and elevated BMI groups

Comparison with Placebo in randomised crossover order; separate sports-drink condition

Self-rated sleep quality2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: No exact CI for the overall contrast. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The study tested the specific form, participant group and outcome stated. Possible publication bias: There are no specific data for a separate downgrade. Study methods: 52 of 60 in the analysis, exploratory subgroup.

In healthy working adults, ubiquinol showed no convincing advantage in self-rated sleep in the whole group over eight weeks.

Study findings. In healthy working adults, ubiquinol showed no convincing advantage in self-rated sleep in the whole group over eight weeks.

Studied regimen100 mg/day of ubiquinol100 mg/day of ubiquinol
Duration and population8 weeks60 healthy working adults aged 30–64; 52 in the efficacy analysis (24 versus 28)

Comparison with Placebo

Memory test result2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: The exact CIs allow a small difference in either direction. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The study tested the specific form, participant group and outcome stated. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Substantial attrition and unequal analyses between groups.

In adults aged 60 and over, ubiquinol gave no convincing advantage in the overall memory test result over 90 days.

Study findings. In adults aged 60 and over, ubiquinol gave no convincing advantage in the overall memory test result over 90 days.

Studied regimen200 mg/dayoral ubiquinol, a form of CoQ10
Duration and population90 days111 adults aged 60 and over randomised; memory assessed in 54 with ubiquinol and 44 with placebo.

Comparison with placebo

Information-processing speed2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: The exact CIs allow a small difference in either direction. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The study tested the specific form, participant group and outcome stated. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Substantial attrition and unequal analyses between groups.

Ubiquinol showed no convincing advantage in information-processing speed compared with placebo.

Study findings. Ubiquinol showed no convincing advantage in information-processing speed compared with placebo.

Studied regimen200 mg/dayoral ubiquinol
Duration and population90 days111 adults aged 60 and over allocated to groups; information-processing speed assessed in 48 with ubiquinol and 41 with placebo

Comparison with placebo

Muscle and fat-free mass1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: 120 participants, CI includes both directions. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Mixed populations and measures, including fat-free mass. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Small studies.

Pooling the studies found no convincing advantage in muscle or fat-free mass.

Study findings. Pooling the studies found no convincing advantage in muscle or fat-free mass.

Studied regimenCoQ10, different forms and dosesCoQ10, different forms and doses
Duration and populationDifferent durations120 adults in four trials with a mean or median age of 40 or over, including patients.

Comparison with Control

Body mass index1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: small samples, intervals and uncertain clinical relevance Consistency of results: insufficient data for a separate downgrade. Applicability to the stated group: the specified form, outcome, clinical background and population limit extrapolation Possible publication bias: insufficient data for a separate downgrade. Study methods: limitations in the assessment of design, reporting or attrition

A review of studies in adults found no convincing change in body mass index.

Study findings. A review of studies in adults found no convincing change in body mass index.

Studied regimen100–300 mg/dayoral CoQ10
Duration and population4–24 weeksAdults with different health conditions; 17 trials measuring body mass index.

Comparison with control

Skin hydration1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: 11 per group; the exact between-group estimate was not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: A specific water-soluble product and instrument-measured outcome. Possible publication bias: There are no specific data for a separate downgrade. Study methods: One small experiment, several measurements.

In women aged 45–60, Q10Vital showed no convincing advantage in measured skin hydration over 12 weeks.

Study findings. In women aged 45–60, Q10Vital showed no convincing advantage in measured skin hydration over 12 weeks.

Studied regimen50 or 150 mg/dayCoQ10 Q10Vital for oral use
Duration and population12 weeks33 healthy women aged 45–60; three groups of 11 women

Comparison with placebo

Dermal thickness1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: 11 per group; the exact between-group estimate was not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: A specific water-soluble product and instrument-measured outcome. Possible publication bias: There are no specific data for a separate downgrade. Study methods: One small experiment, several measurements.

Q10Vital showed no convincing advantage in measured dermal thickness compared with placebo.

Study findings. Q10Vital showed no convincing advantage in measured dermal thickness compared with placebo.

Studied regimen50 or 150 mg/dayCoQ10 Q10Vital for oral use
Duration and population12 weeks33 healthy women aged 45–60; three groups of 11 women

Comparison with placebo

Area of wrinkles around the eyes1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: small samples, intervals and uncertain clinical relevance Consistency of results: insufficient data for a separate downgrade. Applicability to the stated group: the specified form, outcome, clinical background and population limit extrapolation Possible publication bias: insufficient data for a separate downgrade. Study methods: limitations in the assessment of design, reporting or attrition

In women aged 45–60, water-soluble Q10Vital reduced the measured area of wrinkles around the eyes over 12 weeks compared with placebo.

Study findings. In women aged 45–60, water-soluble Q10Vital reduced the measured area of wrinkles around the eyes over 12 weeks compared with placebo.

Studied regimen50 or 150 mg/daywater-soluble CoQ10 Q10Vital taken orally as a syrup
Duration and population12 weeks33 healthy women aged 45–60, three groups of 11

Comparison with placebo syrup

Skin response to ultraviolet light1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: small samples, intervals and uncertain clinical relevance Consistency of results: insufficient data for a separate downgrade. Applicability to the stated group: the specified form, outcome, clinical background and population limit extrapolation Possible publication bias: insufficient data for a separate downgrade. Study methods: limitations in the assessment of design, reporting or attrition

Q10Vital showed no advantage in the minimum ultraviolet dose that causes skin redness.

Study findings. Q10Vital showed no advantage in the minimum ultraviolet dose that causes skin redness.

Studied regimen50 or 150 mg/dayCoQ10 Q10Vital for oral use
Duration and population12 weeks33 healthy women aged 45–60; three groups of 11 women

Comparison with placebo

Safety and limitations

Mild insomnia and gastrointestinal disturbances have been reported; short RCTs do not determine rare or long-term risks. 271 reports, including serious ones, have no denominator of users and do not establish causation or frequency. NCCIH warns of potential interactions; individual reports and a small RCT do not reliably establish the magnitude and direction in a particular person. A trial in high-risk pregnant women from week 20 measured pre-eclampsia. It does not establish safety in early pregnancy, during lactation or in children.

Coenzyme Q10 | NCCIH ↗ · Comparative Analysis of L-Carnitine and Coenzyme Q10 Adverse Reaction Reports Using the EudraVigilance Database: Implications for Health and Sports Supplementation ↗ · Coenzyme Q10 supplementation during pregnancy reduces the risk of pre-eclampsia ↗ · Coenzyme Q10 — Drugs and Lactation Database (LactMed) ↗

Interactions

WithEffectActionSource
WarfarinCoQ10 may interact with warfarin and alter its anticoagulant action; the magnitude of the effect in an individual is unknown.Before starting or stopping CoQ10, discuss it with the doctor managing your warfarin treatment; agree on INR monitoring.Coenzyme Q10 | NCCIH ↗
Coenzyme Q10 | Linus Pauling Institute | Oregon State University ↗
InsulinCoQ10 may interact with insulin; the source does not establish the magnitude or direction of the effect.Before starting CoQ10, discuss the supplement with the doctor managing your insulin treatment.Coenzyme Q10 | NCCIH ↗
Some anticancer medicinesCoQ10 may be incompatible with some types of anticancer treatment.Discuss the supplement with your oncologist before starting it.Coenzyme Q10 | NCCIH ↗

Food sources

Portions help compare foods. For broccoli and oils, CoQ10 per 100 g was approximately calculated from rounded LPI portions. For pork offal, values refer to the raw food before cooking. The composition of individual products may differ.

Meat and poultry

CoQ10 is found in beef and chicken.

Coenzyme Q10 | Linus Pauling Institute | Oregon State University ↗

Fish

Sources of CoQ10 include herring and rainbow trout.

Coenzyme Q10 | Linus Pauling Institute | Oregon State University ↗

Vegetable oils

CoQ10 is present in soybean, corn, olive and rapeseed oils.

Coenzyme Q10 | Linus Pauling Institute | Oregon State University ↗

Nuts and seeds

CoQ10 is found in peanuts, pistachios and sesame seeds.

Coenzyme Q10 | Linus Pauling Institute | Oregon State University ↗

Vegetables, fruit, eggs and dairy products

CoQ10 is also present in broccoli, cauliflower, oranges, strawberries, eggs and dairy products.

Coenzyme Q10 | Linus Pauling Institute | Oregon State University ↗

Food composition

FoodGroupAmountServingCaloriesSources
Pork heartraw, edible portion, before cookingMeat and offal11.81 mg of total CoQ10 (ubiquinone and ubiquinol) / 100 g100 g · 11.81 mg of total CoQ10 (ubiquinone and ubiquinol) · 118 kcalSelected comparison weight: 100 g of raw food before cooking.118 kcal / 100 gThe Quality Control Assessment of Commercially Available Coenzyme Q10-Containing Dietary and Health Supplements in Japan ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 10 ↗
Pork liverraw, edible portion, before cookingMeat and offal5.4 mg of total CoQ10 (ubiquinone and ubiquinol) / 100 g100 g · 5.4 mg of total CoQ10 (ubiquinone and ubiquinol) · 134 kcalSelected comparison weight: 100 g of raw food before cooking.134 kcal / 100 gThe Quality Control Assessment of Commercially Available Coenzyme Q10-Containing Dietary and Health Supplements in Japan ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 10 ↗
Broccoliboiled, chopped; salt not specifiedVegetables0.64 mg of CoQ10 (approximate, calculated) / 100 g78 g · 0.5 mg of CoQ10 (approximate, calculated) · 27.3 kcalPortion: 1/2 cup chopped, boiled; weight from the same USDA food category: .5 cup, chopped = 78 g. The LPI CoQ10 value is rounded.35 kcal / 100 gCoenzyme Q10 | Linus Pauling Institute | Oregon State University ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015), food group 11 ↗
Soybean oiledible, refining method not specifiedVegetable oils9.6 mg of CoQ10 (approximate, calculated) / 100 g13.6 g · 1.3 mg of CoQ10 (approximate, calculated) · 120.2 kcalPortion: 1 tablespoon edible soybean oil; weight from the same USDA food category: 1 tbsp = 13.6 g. The LPI CoQ10 value is rounded.884 kcal / 100 gCoenzyme Q10 | Linus Pauling Institute | Oregon State University ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015), food group 04 ↗
Canola oiledible, refining method not specifiedVegetable oils7.1 mg of CoQ10 (approximate, calculated) / 100 g14 g · 1 mg of CoQ10 (approximate, calculated) · 123.8 kcalPortion: 1 tablespoon canola oil; weight from the same USDA food category: 1 tbsp = 14.0 g. The LPI CoQ10 value is rounded.884 kcal / 100 gCoenzyme Q10 | Linus Pauling Institute | Oregon State University ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015), food group 04 ↗

Studies

PublicationWhat was studiedParticipantsForm and doseResult
A Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Effects of Commercially Available Ubiquinone, Ubiquinol, and Geranylgeraniol Dietary Supplements on Plasma CoQ10 Concentrations ↗Feeling of vigour: Feeling of vigour Vitality questionnaire score: Vitality questionnaire score General health questionnaire score: General health questionnaire scoreFeeling of vigour: 150 healthy adults aged 40 and over allocated to five groups Vitality questionnaire score: 150 healthy adults aged 40 and over allocated to five groups General health questionnaire score: 150 healthy adults aged 40 and over allocated to five groupsFeeling of vigour: 200 mg/day of ubiquinone or 200 mg/day of ubiquinol, separate groups, with food; 200 mg/day of ubiquinone or 200 mg/day of ubiquinol, separate groups, with food; 8 weeks; comparison: Placebo Vitality questionnaire score: 200 mg/day of ubiquinone or 200 mg/day of ubiquinol, separate groups, with food; 200 mg/day of ubiquinone or 200 mg/day of ubiquinol, separate groups, with food; 8 weeks; comparison: Placebo General health questionnaire score: 200 mg/day of ubiquinone or 200 mg/day of ubiquinol, separate groups, with food; 200 mg/day of ubiquinone or 200 mg/day of ubiquinol, separate groups, with food; 8 weeks; comparison: PlaceboFeeling of vigour: In healthy adults aged 40 and over, neither ubiquinone nor ubiquinol showed a convincing advantage in the vigour rating over eight weeks. Vitality questionnaire score: Neither ubiquinone nor ubiquinol showed a convincing advantage in the vitality rating compared with placebo. General health questionnaire score: Neither ubiquinone nor ubiquinol showed a convincing advantage in the general health rating compared with placebo.
Effectiveness of Coenzyme Q10 Supplementation for Reducing Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Trials ↗Fatigue in healthy adultshealthy adults, three studies in the subgroupStudies in healthy participants in the review: Morikawa — ubiquinol 100 mg/day, 8 weeks; Mizuno — ubiquinol 100 or 150 mg/day, 12 weeks; Mousavi — CoQ10 200 mg/day, 4 weeks. Each comparison used placebo.Pooling three studies in healthy adults showed no convincing reduction in subjective fatigue.

Sources

Sources
  1. A Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Effects of Commercially Available Ubiquinone, Ubiquinol, and Geranylgeraniol Dietary Supplements on Plasma CoQ10 Concentrations ↗
  2. Effectiveness of Coenzyme Q10 Supplementation for Reducing Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Trials ↗
  3. Effect of six weeks ubiquinol supplementation on mitochondrial respiratory function and exercise capacity in healthy males ↗
  4. The effects of coenzyme Q10 supplementation on exercise-induced oxidative stress and related physiological outcomes in athletes: a systematic review and meta-analysis ↗
  5. Effects of Coenzyme Q10 Supplementation on Muscle Health and Physical Capacity in Middle-Aged and Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials ↗
  6. Post-workout supplementation with CoQ10 and sports drink on exercise performance and muscle recovery after exercise in normal and overweight males ↗
  7. Reduced Form of Coenzyme Q10 Relieves Daily Life Stress and Improves Sleep Quality in Healthy Subjects with High Stress Sensitivity ↗
  8. Effect of Ubiquinol on Cognitive Function, Blood Pressure, Arterial Stiffness, and Biomarkers of Oxidative Stress and Inflammation in the Elderly: A Randomized Trial ↗
  9. Effects of Coenzyme Q10 Supplementation on Anthropometric Indices in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials ↗
  10. The effect of dietary intake of coenzyme Q10 on skin parameters and condition: Results of a randomised, placebo-controlled, double-blind study ↗
  11. [Effect of Coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial] ↗
  12. Coenzyme Q10 | NCCIH ↗
  13. Coenzyme Q10 supplementation during pregnancy reduces the risk of pre-eclampsia ↗
  14. FDA UNII registry record: UBIDECARENONE (UNII EJ27X76M46) ↗
  15. Comparative Analysis of L-Carnitine and Coenzyme Q10 Adverse Reaction Reports Using the EudraVigilance Database: Implications for Health and Sports Supplementation ↗
  16. Coenzyme Q10 — Drugs and Lactation Database (LactMed) ↗
  17. Comparative Bioavailability of Different Coenzyme Q10 Formulations in Healthy Elderly Individuals ↗
  18. Coenzyme Q10 | Linus Pauling Institute | Oregon State University ↗
  19. The Quality Control Assessment of Commercially Available Coenzyme Q10-Containing Dietary and Health Supplements in Japan ↗
  20. USDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 10 ↗
  21. USDA National Nutrient Database for Standard Reference, Release 28 (2015), food group 11 ↗
  22. USDA National Nutrient Database for Standard Reference, Release 28 (2015), food group 04 ↗